Up 32%: Time to Buy Bluebird Bio?
Bluebird bio shareholders had a great day today, with the stock up 32% on some early stage data for LentiGlobin from its HGB-205 study examining the drug as a treatment for beta-thalassemia major. Two patients in the trial have gone off blood transfusions, a new development that has investors excited about the treatment's potential.
So, is the stock a buy?
In the video below, from Market Checkup, the Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson give their answer.
Leaked: This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need to Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW.
The article Up 32%: Time to Buy Bluebird Bio? originally appeared on Fool.com.David Williamson has no position in any stocks mentioned. Michael Douglass owns shares of Celgene. The Motley Fool recommends Celgene. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.